The Sensitivity of Activated Cys Ret Mutants to Glial Cell Line-Derived Neurotrophic Factor Is Mandatory To Rescue Neuroectodermic Cells from Apoptosis

REFERENCES

• Angrist, M., S. Bolk, B. Thiel, E. G. Puffenberger, R. M. Hofstra, C. H. C. M. Buys, D. T. Cass, and A. Chakravarti. 1995. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung's disease. Hum. Mol. Genet. 4:821–830.
   PubMed Web of Science ®Google Scholar
• Asai, N., T. Iwashita, M. Matsuyama, and M. Takahashi. 1995. Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol. 15:1613–1619.
   PubMed Web of Science ®Google Scholar
• Besset, V., R. P. Scott, and C. F. Ibanez. 2000. Signaling complexes and protein-protein interactions involved in the activation of the Ras and PI3K pathways by the c-Ret receptor tyrosine kinase. J. Biol. Chem. 275:39159–39166.
   PubMedGoogle Scholar
• Bocciardi, R., B. Mograbi, B. Pasini, M. G. Borrello, M. A. Pierotti, I. Bourget, S. Fisher, G. Romeo, and B. Rossi. 1997. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15:2257–2265.
   PubMed Web of Science ®Google Scholar
• Bolk, S., A. Pelet, R. M. W. Hofstra, M. Angrist, R. Salomon, D. Croaker, C. H. C. M. Buys, S. Lyonnet, and A. Chakravarti. 2000. A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc. Natl. Acad. Sci. USA 97:268–273.
   PubMed Web of Science ®Google Scholar
• Bongarzone, I., E. Vigano, L. Alberti, P. Mondellini, M. Uggeri, B. Pasini, M. G. Borrello, and M. A. Pierotti. 1999. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Oncogene 18:4833–4838.
   PubMedGoogle Scholar
• Borrego, S., M. E. Saez, A. Ruiz, O. Gimm, M. Lopez-Alonso, G. Antinolo, and C. Eng. 1999. Specific polymorphisms in the RET proto-oncogene are overrepresented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J. Med. Genet. 36:771–774.
   PubMedGoogle Scholar
• Borrello, M. G., D. P. Smith, B. Pasini, I. Bongazone, A. Greco, M. J. Lorenzo, E. Arighi, C. Miranda, C. Eng, L. Alberti, R. Bocciardi, P. Mondellini, L. Scopsi, G. Romeo, B. A. J. Ponder, and M. A. Pierotti. 1995. RET activation by germ-line MEN2A and MEN2B mutations. Oncogene 11:2419–2427.
   PubMedGoogle Scholar
• Cacalano, G., I. Farinas, L. C. Wang, K. Hagler, A. Forgie, M. Moore, M. Armanini, H. Phillips, A. M. Ryan, L. F. Reichardt, M. Hynes, A. Davies, and A. Rosenthal. 1998. GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron 21:53–62.
   PubMed Web of Science ®Google Scholar
• Carlomagno, F., R. M. Melillo, R. Visconti, G. Salvatore, G. De Vita, G. Lupoli, Y. Yu, S. Jing, G. Vecchio, A. Fusco, and M. Santoro. 1998. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology 139:3613–3619.
   PubMedGoogle Scholar
• Carlomagno, F., G. Salvatore, A. M. Cirafici, G. De Vita, R. M. Melillo, V. De Franciscis, M. Billaud, A. Fusco, and M. Santoro. 1997. The different RET-activating capability of mutations of cysteine 620 or 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res. 57:391–395.
   PubMedGoogle Scholar
• Carlson, K. M., S. Dou, S. Chi, N. Scavarda, K. Toshima, C. E. Jackson, S. A. J. Wells, P. J. Goodfellow, and H. Donis-Keller. 1994. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with Multiple Neoplasia type 2B. Proc. Natl. Acad. Sci. USA 91:1579–1583.
   PubMed Web of Science ®Google Scholar
• Chappuls-Flament, S., A. Pasini, G. De Vita, C. Ségouffin-Cariou, A. Fusco, T. Attié, G. M. Lenoir, M. Santoro, and M. Billaud. 1998. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic residues. Oncogene 17:2851–2861.
   PubMedGoogle Scholar
• Decker, R. A., M. L. Peacock, and P. Watson. 1998. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum. Mol. Genet. 7:129–134.
   PubMedGoogle Scholar
• Donis-Keller, H., S. Dou, D. Chi, K. M. Carlson, K. Toshima, T. C. Lairmore, J. R. Howe, J. F. Moley, P. Goodfellow, and S. A. J. Wells. 1993. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2:851–856.
   PubMed Web of Science ®Google Scholar
• Eng, C., D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R. F. Gagel, H. K. Ploos van Amstel, C. J. M. Lips, I. Nishisho, S.-I. Takai, D. J. Marsh, B. G. Robinson, F. Frank-Raue, F. Xue, W. W. Noll, G. Romeo, F. Pacini, M. Fink, B. Niederle, J. Zedenius, M. Nordenskjold, P. Komminoth, G. N. Hendy, H. Gharib, S. N. Thibodeau, A. Lacroix, A. Frilling, B. A. J. Ponder, and L. M. Mulligan. 1996. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 276:1575–1579.
   PubMed Web of Science ®Google Scholar
• Enomoto, H., T. Araki, A. Jackman, R. O. Heuckeroth, W. D. Snider, E. M. J. Johnson, and J. Milbrandt. 1998. GFRalphal-deficient mice have deficits in the enteric nervous system and kidneys. Neuron 21:317–324.
   PubMed Web of Science ®Google Scholar
• Fitze, G., M. Schreiber, E. Kuhlisch, H. K. Schackert, and D. Roesner. 1999. Association of RET proto-oncogene codon 45 polymorphism with Hirschsprung disease. Am. J. Hum. Genet. 65:1469–1473.
   PubMedGoogle Scholar
• Geneste, O., C. Bidaud, G. De Vita, R. M. W. Hofstra, S. Tartare-Deckert, C. H. C. M. Buys, G. M. Lenoir, M. Santoro, and M. Billaud. 1999. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. Hum. Mol. Genet. 8:1989–1999.
   PubMedGoogle Scholar
• Griseri, P., M. Sancandi, G. Patrone, R. Bocciardi, R. Hofstra, R. Ravazzolo, M. Devoto, G. Romeo, and I. Ceccherini. 2000. A single-nucleotide polymorphic variant of the RET proto-oncogene is underrepresented in sporadic Hirschsprung disease. Eur. J. Hum. Genet. 8:721–724.
   PubMedGoogle Scholar
• Hayashi, H., M. Ichihara, T. Iwashita, H. Murakami, Y. Shimono, K. Kawai, K. Kurokawa, Y. Murakumo, T. Imai, H. Funahashi, A. Nakao, and M. Takahashi. 2000. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19:4469–4475.
   PubMedGoogle Scholar
• Hofstra, R. M. W., R. M. Landsvater, I. Ceccherini, R. P. Stulp, T. Stelwagen, L. Yin, B. Pasini, J. W. M. Hoppener, H. K. Ploos van Amstel, G. Romeo, C. J. M. Lips, and C. H. C. M. Buys. 1994. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary carcinoma. Nature 367:375–376.
   PubMed Web of Science ®Google Scholar
• Hofstra, R. M. W., J. Osinga, and C. H. C. M. Buys. 1997. Mutations in Hirschsprung disease: when does a mutation contribute to the phenotype. Eur. J. Hum. Genet. 5:180–185.
   PubMedGoogle Scholar
• Ito, S., T. Iwashita, N. Asai, H. Murakami, Y. Iwata, G. Sobue, and M. Takahashi. 1997. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary carcinoma, and Hirschsprung disease. Cancer Res. 57:2870–2872.
   PubMedGoogle Scholar
• Iwashita, T., N. Asai, H. Murakami, M. Matsuyama, and M. Takahashi. 1996. Identification of tyrosine residues that are essential for transforming activity for the Ret proto-oncogene with the MEN2A or MEN2B mutations. Oncogene 12:481–487.
   PubMed Web of Science ®Google Scholar
• Jarpe, M. B., C. Widmann, C. Knall, T. K. Schesinger, S. Gibson, T. Yujiri, G. R. Fanger, E. W. Gelfand, and G. L. Johnson. 1998. Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17:1475–1482.
   PubMed Web of Science ®Google Scholar
• Jiang, G., and T. Hunter. 1999. Receptor signaling: when dimerization is not enough. Curr. Biol. 9:R568–R571.
   PubMed Web of Science ®Google Scholar
• Jing, S. J., D. Wen, Y. Yu, P. L. Holst, Y. Luo, M. Fang, R. Tamir, L. Antonio, Z. Hu, R. Cupples, J. Louis, S. Hu, B. Altrock, and G. M. Fox. 1996. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85:1113–1124.
   PubMed Web of Science ®Google Scholar
• Liu, X., Q. C. Vega, R. A. Decker, A. Pandey, C. A. Worby, and J. E. Dixon. 1996. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J. Biol. Chem. 271:5309–5312.
   PubMedGoogle Scholar
• Moore, M. W., R. D. Klein, I. Fariñas, H. Sauer, M. Armanini, H. Phillips, L. F. Reichardt, A. M. Ryan, K. Carver-Moore, and A. Rosenthal. 1996. Renal and neuronal abnormalities in mice lacking GDNF. Nature 382:76–79.
   PubMed Web of Science ®Google Scholar
• Mulligan, L. M., C. Eng, T. Attié, S. Lyonnet, D. J. Marsh, V. J. Hyland, B. G. Robinson, A. Frilling, C. Verellen-Dumoulin, A. Safar, D. J. Venter, A. Munnich, and B. A. J. Ponder. 1994. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum. Mol. Genet. 3:2163–2167.
   PubMedGoogle Scholar
• Mulligan, L. M., C. Eng, S. C. Healy, D. Clayton, J. B. Kwock, E. Gardner, M. A. Ponder, A. Frilling, C. E. Jackson, H. Lehnert, H. P. H. Neumann, S. N. Thibodeau, and B. A. Ponder. 1994. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet 6:70–74.
   PubMed Web of Science ®Google Scholar
• Mulligan, L. M., J. B. Kwock, S. C. Healy, M. J. Eldson, C. Eng, E. Gardner, D. R. Love, S. E. Mole, J. K. Moore, L. Papi, M. A. Ponder, H. Telenius, A. Tunnacliffe, and B. A. J. Ponder. 1993. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–460.
   PubMed Web of Science ®Google Scholar
• Pachnis, V., B. Mankoo, and F. Costantini. 1993. Expression of the c-RET proto-oncogene during mouse embryogenesis. Development 119:1005–1017.
   PubMed Web of Science ®Google Scholar
• Pandit, S. B., H. Donis-Keller, T. Iwamoto, J. M. Tomich, and L. J. Pike. 1996. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor. J. Biol. Chem. 271:5850–5858.
   PubMedGoogle Scholar
• Pasini, B., M. G. Borrello, A. Greco, I. Bongarzone, Y. Luo, P. Mondellini, L. Alberti, C. Miranda, E. Arighi, R. Bocciardi, M. Seri, V. Barone, M. T. Radice, G. Romeo, and M. A. Pierotti. 1995. Loss of function effect of RET mutations causing Hirschsprung disease. Nat. Genet. 10:35–40.
   PubMed Web of Science ®Google Scholar
• Pasini, B., I. Ceccherini, and G. Romeo. 1996. RET mutations in human disease. Trends Genet. 12:138–144.
   PubMed Web of Science ®Google Scholar
• Pelet, A., O. Geneste, P. Edery, A. Pasini, S. Chappuis, T. Atti, A. Munnich, G. Lenoir, S. Lyonnet, and M. Billaud. 1998. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J. Clin. Investig. 101:1415–1423.
   PubMedGoogle Scholar
• Peretz, H., R. Luboshitsky, E. Baron, A. Biton, R. Gershoni, S. Usher, E. Grynberg, E. Yakobson, E. Graff, and M. Lapidot. 1997. Cys618→Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum. Mutat. 10:155–159.
   PubMedGoogle Scholar
• Pichel, J. G., L. Shen, H. Z. Sheng, A.-C. Granholm, J. Drago, A. Grinberg, E. J. Lee, S. P. Huang, M. Saarma, B. J. Hoffer, H. Sariola, and H. Westphal. 1996. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382:73–76.
   PubMed Web of Science ®Google Scholar
• Ponder, B. A. J.. 1999. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res. 59:1736S–1742S.
   PubMedGoogle Scholar
• Romeo, G., I. Ceccherini, J. Celli, M. Priolo, N. Betsos, G. Bonardi, M. Seri, L. Yin, M. Lerone, V. Jasonni, and G. Martucciello. 1998. Association of multiple endocrine neoplasia type 2 and HSCR disease. J. Intern. Med. 243:515–520.
   PubMedGoogle Scholar
• Sánchez, M. P., I. Silos-Santiago, J. Frisén, H. Bin, S. A. Lira, and M. Barbacid. 1996. Renal agenesis and absence of enteric neurons in mice lacking GDNF. Nature 382:70–73.
   PubMed Web of Science ®Google Scholar
• Santoro, M., F. Carlomagno, A. Romano, D. P. Bottaro, N. A. Datham, M. Grieco, A. Fusco, G. Vacchio, B. Matoskova, M. H. Kraus, and P. P. Di Fiore. 1995. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381–383.
   PubMed Web of Science ®Google Scholar
• Santoro, M., W. T. Wong, P. Aroca, E. Santos, B. Matoskova, M. Grieco, A. Fusco, and P. P. Di Fiore. 1994. An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific pathway. Mol. Cell. Biol. 14:663–675.
   PubMed Web of Science ®Google Scholar
• Schuchardt, A., V. D'Agati, L. Larsson-Blomberg, F. Costantini, and V. Pachnis. 1995. RET-deficient mice: a animal model for Hirschsprung's disease and renal agenesis. J. Intern. Med. 238:327–332.
   PubMedGoogle Scholar
• Segouffin-Cariou, C., and M. Billaud. 2000. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J. Biol. Chem. 275:3568–3576.
   PubMed Web of Science ®Google Scholar
• Songyang, Z., I. K. L. Carraway, M. J. Eck, S. C. Harrison, R. A. Feldman, M. Mohammadi, J. Schlessinger, S. R. Hubbard, D. P. Smith, C. Eng, M. J. Lorenzo, B. A. J. Ponder, B. J. Mayer, and L. C. Cantley. 1995. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536–539.
   PubMed Web of Science ®Google Scholar
• Takahashi, M., T. Iwashita, M. Santoro, S. Lyonnet, G. M. Lenoir, and M. Billaud. 1999. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?. Hum. Mutat. 13:331–336.
   PubMedGoogle Scholar
• Tansey, M. G., R. H. Baloh, J. Milbrandt, and E. M. J. Johnson. 2000. GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 3:611–623.
   Google Scholar
• Taraviras, S., C. V. Marcos-Gutierrez, P. Durbec, H. Jani, M. Grigoriou, M. Sukumaran, L. C. Wang, M. Hynes, G. Raisman, and V. Pachnis. 1999. Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Development 126:2785–2797.
   PubMed Web of Science ®Google Scholar
• Treanor, J. J. S., L. Goodman, F. de Sauvage, D. M. Stone, K. T. Poulsen, C. D. Beck, C. Gray, M. P. Armanini, R. A. Pollock, F. Hefti, H. S. Phillips, A. Goddard, M. W. Moore, A. Buj-Bello, A. M. Davies, N. Asai, M. Takahashi, R. Vandlen, E. H. Henderson, and A. Rosenthal. 1996. Characterization of a multicomponent receptor for GDNF. Nature 382:80–83.
   PubMed Web of Science ®Google Scholar
• Trupp, M., E. Arenas, M. Fainzilber, A. Nilsson, B. A. Sieber, M. Grigoriou, C. Kilkenny, E. Salazar-Gruesco, V. Pachnis, U. Arumae, H. Sariola, M. Saarma, and C. F. Ibáñez. 1996. Functional receptor for glial cell line-derived neurotrophic factor encoded by the c-ret proto-oncogene product. Nature 381:785–789.
   PubMed Web of Science ®Google Scholar
• Tsuzuki, T., M. Takahashi, N. Asai, T. Iwashita, M. Matsuyama, and J. Asai. 1995. Spatial and temporal expression of the RET proto-oncogene product in embryonic, infant and adult rat tissue. Oncogene 10:191–198.
   PubMed Web of Science ®Google Scholar
• van Weering, D. H. J., and J. L. Bos. 1997. Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. J. Biol. Chem. 272:249–254.
   PubMedGoogle Scholar
• van Weering, D. H. J., T. C. Moen, I. Braakman, P. D. Baas, and J. L. Bos. 1998. Expression of the receptor tyrosine kinase Ret on the plasma membrane is dependent on calcium. J. Biol. Chem. 273:12077–12081.
   PubMedGoogle Scholar
• Xing, S., T. L. Furminger, Q. Tong, and S. M. Jhiang. 1998. Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells. J. Biol. Chem. 273:4909–4914.
   PubMedGoogle Scholar
• Yu, T., S. Scully, Y. Yu, G. M. Fox, S. Jing, and R. Zhou. 1998. Expression of GDNF family receptor components during development: implications in the mechanisms of interaction. J. Neurosci. 18:4684–4696.
   PubMed Web of Science ®Google Scholar